ea0063p1076 | Pituitary and Neuroendocrinology 3 | ECE2019
Ferreira Ana
, Oliveira Guilherme
, Bastos Filipa
, Carlos Cordeiro Maria
, Duarte Julia
, Portugal Jorge
Introduction: Prolactinomas are mostly benign tumours usually managed with pharmacological treatment. Some, however, seem to be resistant to dopamine agonists (DA) for unclear reasons. The relationship between T2W signal intensity (T2WSI) and response to treatment with somatostatin analogs is well described in acromegaly patients. Some evidence suggests that prolactinomas T2W hypointensity might be related to higher baseline prolactin levels and more resistance to DA.</p...